SWX:RLF

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief in serious diseases with high unmet medical need. More Details


Snowflake Analysis

Questionable track record with worrying balance sheet.

Share Price & News

How has Relief Therapeutics Holding's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RLF is more volatile than 90% of Swiss stocks over the past 3 months, typically moving +/- 22% a week.

Volatility Over Time: RLF's weekly volatility has decreased from 52% to 22% over the past year, but is still higher than 75% of Swiss stocks.


Market Performance


7 Day Return

7.3%

RLF

3.6%

CH Biotechs

0.4%

CH Market


1 Year Return

30,700.0%

RLF

1.3%

CH Biotechs

-0.4%

CH Market

Return vs Industry: RLF exceeded the Swiss Biotechs industry which returned 1.3% over the past year.

Return vs Market: RLF exceeded the Swiss Market which returned -0.4% over the past year.


Shareholder returns

RLFIndustryMarket
7 Day7.3%3.6%0.4%
30 Day-17.0%1.5%2.8%
90 Day-42.1%2.0%5.8%
1 Year30,700.0%30,700.0%2.6%1.3%3.1%-0.4%
3 Year1,874.4%1,874.4%4.3%1.9%19.8%4.7%
5 Yearn/a71.8%66.0%51.9%26.8%

Long-Term Price Volatility Vs. Market

How volatile is Relief Therapeutics Holding's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Relief Therapeutics Holding undervalued compared to its fair value and its price relative to the market?

488.11x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate RLF's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate RLF's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: RLF is poor value based on its PE Ratio (488.1x) compared to the XE Biotechs industry average (43.3x).

PE vs Market: RLF is poor value based on its PE Ratio (488.1x) compared to the Swiss market (24.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RLF's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RLF is overvalued based on its PB Ratio (28.3x) compared to the CH Biotechs industry average (3x).


Next Steps

Future Growth

How is Relief Therapeutics Holding forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

24.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Relief Therapeutics Holding has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Relief Therapeutics Holding performed over the past 5 years?

44.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RLF has a high level of non-cash earnings.

Growing Profit Margin: RLF became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: RLF has become profitable over the past 5 years, growing earnings by 44.6% per year.

Accelerating Growth: RLF has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: RLF has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (7.3%).


Return on Equity

High ROE: RLF's Return on Equity (5.6%) is considered low.


Next Steps

Financial Health

How is Relief Therapeutics Holding's financial position?


Financial Position Analysis

Short Term Liabilities: RLF's short term assets (CHF3.1M) do not cover its short term liabilities (CHF5.8M).

Long Term Liabilities: RLF's short term assets (CHF3.1M) do not cover its long term liabilities (CHF4.3M).


Debt to Equity History and Analysis

Debt Level: RLF's debt to equity ratio (14%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if RLF's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: RLF's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if RLF's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is Relief Therapeutics Holding current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RLF's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RLF's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RLF's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RLF's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RLF's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.3yrs

Average management tenure


CEO

Relief Therapeutics Holding has no CEO, or we have no data on them.


Leadership Team

NamePositionTenureCompensationOwnership
Jack Weinstein
CFO & Treasurer0.25yrno datano data
Jeremy Meinen
Vice President of Finance & Administration0.75yrno datano data
Gilles Corte
Chief Medical Officer0.33yrno datano data
Christiaan L. J. Stijnen
Chief Commercial Officer0.083yrno datano data

0.3yrs

Average Tenure

Experienced Management: RLF's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Raghuram Selvaraju
Chairman of the Board4.67yrsno datano data
Thomaz Burckhardt
Director1.58yrsno datano data
Thomas Plitz
Director0.083yrno datano data

1.6yrs

Average Tenure

52yo

Average Age

Experienced Board: RLF's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 53.6%.


Top Shareholders

Company Information

Relief Therapeutics Holding AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Relief Therapeutics Holding AG
  • Ticker: RLF
  • Exchange: SWX
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CHF999.992m
  • Shares outstanding: 3.25b
  • Website: https://www.relieftherapeutics.com

Number of Employees


Location

  • Relief Therapeutics Holding AG
  • Fondation EIP
  • BAtiment F2/F3
  • Geneva
  • Geneva
  • 1202
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RLFSWX (SIX Swiss Exchange)YesRegistered SharesCHCHFJul 2016
RLFT.FOTCPK (Pink Sheets LLC)YesRegistered SharesUSUSDJul 2016

Biography

Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief in serious diseases with high unmet medical need. The company focuses on clinical-stage programs based...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/16 18:05
End of Day Share Price2021/01/15 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.